

Presented at the ACMT Annual Scientific Meeting 2022 – Virtual

Published in J Med Tox 2022; 18:97

#### **074. Snake Bites in Diabetic Patients: A Descriptive Analysis**

Sukhshant K Atti<sup>1,2</sup>, Erin Ryan<sup>2</sup>, William Rushton<sup>1,2</sup>, Michael Beuhler<sup>3</sup>, Kerollos Shaker<sup>4</sup>, Kim Aldy<sup>4,5</sup>, Sharan Campleman<sup>5</sup>, Paul Wax<sup>4,5</sup>, Jeffrey Brent<sup>6</sup>, Michelle Ruha<sup>7</sup>, On Behalf of the Toxicology Investigators Consortium (ToxIC) North American Snakebite Study Group

<sup>1</sup> University of Alabama at Birmingham, Birmingham, Alabama, USA. <sup>2</sup> Alabama Poison Information Center, Birmingham, Alabama, USA. <sup>3</sup> North Carolina Poison Control, Atrium Health, Charlotte, North Carolina, USA. <sup>4</sup> University of Texas Southwestern Medical Center, Dallas, Texas, USA. <sup>5</sup> American College of Medical Toxicology, Phoenix, Arizona, USA. <sup>6</sup> University of Colorado, Aurora, Colorado, USA. <sup>7</sup> Banner-University Medical Center Phoenix, Phoenix, Arizona, USA

**Background:** There is limited literature examining the impact of comorbidities such as diabetes on the clinical course of snake envenomations. This report summarizes characteristics of snake envenomations in patients with diabetes.

**Methods:** All cases reported to the Toxicology Investigators Consortium North American Snakebite Registry between 2013 and 2020 in patients with a history of diabetes were reviewed, and data on demographics, clinical effects, treatments, and outcomes were extracted.

**Results:** Thirty-four cases from 10 states were identified. Median age was 46.5 years (range 3-75 years) and 67.6% (n = 23) were male. The majority of patients (n = 26, 76.5%) had at least one additional comorbidity. Most bites involved rattlesnakes (n = 18, 52.9%) or copperheads (n = 10, 29.4%), and there were equal numbers of upper and lower extremity bites. The most common effects were swelling (n = 32, 94.1%) and ecchymosis (N22, 64.7%). Hemotoxicity (platelets < 170, or PT >15) occurred in 20.6% (n = 7) of patients initially and 20.6% (n = 7) at follow up. Three patients (8.82%) developed necrosis; two required procedures (debridement, incision and drainage, and/or skin graft). Hypotension was noted in five patients (14.7%) but resolved with IV fluid resuscitation in all but one. Two patients (5.88%) required mechanical ventilation. Antivenom was administered in 88.2% (n = 30) of cases with a median total dose of 10 vials (range 4-53 vials; IQR 6-13.5 vials). Hospital length of stay was < 48 hours in 82.4% (n = 28) of patients and < 24 hours in 41.2% (n = 14); 41.2% (n = 14) were admitted to an intensive care unit. At final follow up (up to three weeks from initial bite), seven patients (20.6%) had residual functional deficits and one (2.94%) suffered permanent tissue loss.

**Conclusion:** The majority of snake envenomations in diabetes patients described in this report required treatment with antivenom and most had short hospital stays.